Epoprostenol vs Treprostinil (Orenitram)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Epoprostenol · Flolan

Rights held by GlaxoSmithKline; US product discontinued

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Treprostinil (Orenitram)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00325403 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.

Reported efficacy

Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)

Result source: NCT00325403

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Epoprostenol: 6 of 7 rows · Treprostinil (Orenitram): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEpoprostenol
Rows use multiple source trials
Treprostinil (Orenitram)
Rows use multiple source trials
6MWD - Change
absolute change · m
288 vs 323.5 Epoprostenol Sodium for Injection m @ 4wka,b,c,d
NCT01105091 · Phase 4 · registry result, not featured evidence
395.4 vs 372.3 placebo m @ 24wka,b,c,d
NCT01560624 · Phase 3 · registry result, not featured evidence
6MWD - Change
absolute change · m
No placebo or comparator arm
-3.55 m @ 4wke,f,d
NCT01462565 · Phase 4 · registry result, not featured evidence
2.7 m @ 24wkg,e,f,d
NCT02276872 · Phase 2 · registry result, not featured evidence
show 2 more doses
22.1 m @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
12.8 m @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Borg Dyspnea
absolute change · score
No placebo or comparator arm
0.36 score @ 4wka,b,c,h
NCT01462565 · Phase 4 · registry result, not featured evidence
-0.49 score @ 48wka,b,c,h
NCT01560637 · Phase 3 · registry result, not featured evidence
Dropout rate
0%i
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
10%
NCT01105091 · Phase 4 · registry result, not featured evidence
21.9%j
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
42.1%
NCT01560637 · Phase 3 · registry result, not featured evidence
76.7%
NCT01027949 · Phase 3 · registry result, not featured evidence
57.2%
NCT01560624 · Phase 3 · registry result, not featured evidence
12.1%
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—i
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT01105117 · Phase 4 · registry result, not featured evidence
—
NCT01105091 · Phase 4 · registry result, not featured evidence
—j
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
13.4%
NCT01560637 · Phase 3 · registry result, not featured evidence
19.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
—
NCT01560624 · Phase 3 · registry result, not featured evidence
—
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
12.5%i
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
30%
NCT01105091 · Phase 4 · registry result, not featured evidence
17.9%j
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
43.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
61.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
33.5%
NCT01560624 · Phase 3 · registry result, not featured evidence
18.4%
NCT00325442 · Phase 3 · registry result, not featured evidence
50%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
33.3%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
diarrhoea 12.5%
fatigue 12.5%
headache 12.5%
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
catheter site erythema 100%
flushing 0%
NCT01105117 · Phase 4 · registry result, not featured evidence
pain in jaw 75%
headache 65%
nausea 50%
NCT01105091 · Phase 4 · registry result, not featured evidence
j
headache 62.9% (placebo 19.5%)
diarrhea 30.5% (placebo 15.6%)
nausea 29.8% (placebo 18.2%)
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
headache 69.8%
diarrhoea 66.2%
flushing 42.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
headache 78.1%
diarrhoea 66.2%
nausea 56.5%
NCT01027949 · Phase 3 · registry result, not featured evidence
headache 74.9% (placebo 34.9%)
diarrhoea 69.4% (placebo 28.5%)
flushing 44.5% (placebo 7.8%)
NCT01560624 · Phase 3 · registry result, not featured evidence
headache 86.2% (placebo 36.9%)
nausea 64.4% (placebo 34.1%)
diarrhea 60.9% (placebo 27.3%)
NCT00325442 · Phase 3 · registry result, not featured evidence
vomiting 90%
nausea 70%
diarrhoea 60%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 80%
diarrhoea 70%
cough 50%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 100%
diarrhoea 75%
nausea 75%
NCT02276872 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 4 weeks versus 24 weeks.
  5. eTrial phases differ: Phase 4 versus Phase 2.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  8. hAssessment timepoints differ: 4 weeks versus 48 weeks.
  9. iPopulation comparability has not been reviewed for these studies.
  10. jPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Epoprostenol

SF-36 Physical Functioning -1.156 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Physical -0.765 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Physical
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Emotional 0.002 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Emotional
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Vitality 0.781 score @ 4wk
absolute change · score
No placebo or comparator arm
Vitality
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Social Functioning 1.706 score @ 4wk
absolute change · score
No placebo or comparator arm
Social Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Bodily Pain 3.065 score @ 4wk
absolute change · score
No placebo or comparator arm
Bodily Pain
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 General Health -0.606 score @ 4wk
absolute change · score
No placebo or comparator arm
General Health
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Physical Component Summary -0.123 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Health Component
NCT01462565 · Phase 4 · registry result, not featured evidence
SvO2 58% (n=11) vs 56% (n=6) Epoprostenol Sodium for Injection @ 4wk
absolute change · percentage points
NCT01105091 · Phase 4 · registry result, not featured evidence

Treprostinil (Orenitram)

6MWD - Change 25 vs -5 placebo m @ 12wk
absolute change · m
Change in 6MWD from Baseline to Week 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
16.5 vs 5.8 placebo m @ 12wk
Change in 6MWD from Baseline to Week 12
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 8 vs 0 placebo m @ 11wk
absolute change · m
Change in 6MWD from Baseline to Week 11
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
6MWD - Change 17 vs 0 placebo m @ 8wk
absolute change · m
Change in 6MWD from Baseline to Week 8
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
15 vs 7 placebo m @ 8wk
Change in 6MWD from Baseline to Week 8
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 7 vs 0 placebo m @ 4wk
absolute change · m
Change in 6MWD from Baseline to Week 4
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
5.5 vs 2.1 placebo m @ 4wk
Change in 6MWD from Baseline to Week 4
NCT00325442 · Phase 3 · registry result, not featured evidence
Clinical Worsening 9.9% (n=151) vs 10.4% (n=77) placebo @ 12wk
event count · % of participants
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 · converted to % from 15 participants as posted
show 1 more result
4.6% (n=174) vs 6.8% (n=176) placebo @ 16wk*
NCT00325442 · Phase 3 · registry result, not featured evidence · converted to % from 8 participants as posted
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change in Borg dyspnea score from Baseline to Wk12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Dyspnea-Fatigue Index -0.3 vs -0.3 placebo score @ 12wk
absolute change · score
Change in dyspnea-fatigue index from BL to Wk 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Change 20.1 m @ 48wk
absolute change · m
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
WHO Functional Class -0.2 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
NT-proBNP -179.23 pg/mL @ 48wk
absolute change · pg/mL
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
6MWD - Change 22 m @ 48wk
absolute change · m
Extension (open-label)
No placebo or comparator arm
NCT01027949 · Phase 3 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.98 vs 11.38 placebo months
time to event · months
NCT01560624 · Phase 3 · registry result, not featured evidence · converted to months from 60.58 weeks as posted

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Epoprostenol's landscape · Treprostinil (Orenitram)'s landscape